[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,139,525,504
  • Shares Outstanding, K 941,741
  • Annual Sales, $ 65,179 M
  • Annual Income, $ 20,640 M
  • EBIT $ 31,522 M
  • EBITDA $ 33,519 M
  • 60-Month Beta 0.51
  • Price/Sales 17.64
  • Price/Cash Flow 48.56
  • Price/Book 36.85

Options Overview Details

View History
  • Implied Volatility 43.03% (+0.04%)
  • Historical Volatility 33.13%
  • IV Percentile 84%
  • IV Rank 81.29%
  • IV High 46.75% on 04/15/26
  • IV Low 26.88% on 09/04/25
  • Expected Move (DTE 1) 21.18 (1.82%)
  • Put/Call Vol Ratio 2.29
  • Today's Volume 35,453
  • Volume Avg (30-Day) 45,247
  • Put/Call OI Ratio 1.36
  • Today's Open Interest 353,476
  • Open Int (30-Day) 355,647
  • Expected Range 1,141.55 to 1,183.91

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $6.71
  • Number of Estimates 4
  • High Estimate $8.80
  • Low Estimate $5.83
  • Prior Year $6.31
  • Growth Rate Est. (year over year) +6.34%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1,134.40 +2.54%
on 07/15/26
1,249.45 -6.90%
on 07/07/26
-36.19 (-3.02%)
since 06/30/26
3-Month
943.26 +23.32%
on 05/11/26
1,249.45 -6.90%
on 07/07/26
+228.64 (+24.46%)
since 04/30/26
52-Week
623.78 +86.48%
on 08/08/25
1,249.45 -6.90%
on 07/07/26
+403.16 (+53.04%)
since 07/30/25

Most Recent Stories

More News
3 Quality Compounders to Own for Decades

3 Quality Compounders to Own for Decades

FIX : 1,693.12 (+11.39%)
LLY : 1,156.56 (-4.42%)
DASH : 196.01 (+1.28%)
3 Divine Dividend-Growth ETFs

If you want to diversify your holdings across many dividend growers all at once, check out these dividend-growth ETFs.

MSFT : 456.64 (+16.93%)
LIN : 506.31 (-0.95%)
AVGO : 387.03 (+4.51%)
EFAD : 44.28 (+1.07%)
VIG : 240.07 (+0.63%)
XOM : 157.46 (+0.45%)
LLY : 1,156.56 (-4.42%)
WMT : 110.97 (-2.85%)
NOBL : 57.19 (-1.75%)
ED : 109.59 (-2.37%)
ASML : 1,651.56 (+6.50%)
Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C

In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost up to an average of 49.6 lbs (20.8%) at 80 weeks

LLY : 1,156.56 (-4.42%)
Lilly confirms date and conference call for second-quarter 2026 financial results announcement

INDIANAPOLIS , July 22, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2026 financial results on August 5, 2026. Lilly will also conduct a conference call...

LLY : 1,156.56 (-4.42%)
Insider Moves Are Sending Mixed Signals Across the Tech Sector

Broadcom sees insider selling after volatile 2026 trading, while Netskope draws heavy insider buying post-earnings drop and Eli Lilly CEO David Ricks purchases Adobe shares.

AVGO : 387.03 (+4.51%)
ADBE : 247.48 (-6.05%)
LLY : 1,156.56 (-4.42%)
NTSK : 11.89 (-0.59%)
What You Need to Know Ahead of Eli Lilly's Earnings Release

Eli Lilly will release its second-quarter earnings next month, and analysts anticipate a double-digit bottom-line growth.

XLV : 163.52 (-1.64%)
$SPX : 7,445.94 (+1.77%)
LLY : 1,156.56 (-4.42%)
Novo Nordisk Sues Eli Lilly Over Obesity Drug Advertising Claims

Novo Nordisk ($NVO) filed a lawsuit against Eli Lilly ($LLY), alleging Lilly's advertising for Zepbound and Mounjaro relies on outdated clinical comparisons that understate the performance of Novo's latest...

NVO : 51.15 (-0.83%)
LLY : 1,156.56 (-4.42%)
How AI-Driven Protein Generation Is a Margin Killer for Drugmakers

The next tech revolution in biotech might save lives, but it could also crush pharmaceutical margins.

GOOGL : 334.09 (-0.78%)
LLY : 1,156.56 (-4.42%)
NVS : 157.93 (-0.57%)
Billions Flow Into Next-Generation Depression Treatments as Pharma Innovation Accelerates

EQNX::TICKER_START (NASDAQ:HELP),(NASDAQ:CMPS),(NASDAQ:ATAI),(NYSE:JNJ),(NYSE:LLY) EQNX::TICKER_END

HELP : 8.04 (+1.64%)
CMPS : 11.38 (+4.40%)
ATAI : 7.20 (+0.28%)
JNJ : 255.92 (-3.62%)
LLY : 1,156.56 (-4.42%)
Eli Lilly (LLY): Buy, Sell, or Hold Post Q1 Earnings?

Eli Lilly (LLY): Buy, Sell, or Hold Post Q1 Earnings?

LLY : 1,156.56 (-4.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure...

See More

Key Turning Points

3rd Resistance Point 1,248.93
2nd Resistance Point 1,239.06
1st Resistance Point 1,224.54
Last Price 1,156.56
1st Support Level 1,200.15
2nd Support Level 1,190.28
3rd Support Level 1,175.76

See More

52-Week High 1,249.45
Last Price 1,156.56
Fibonacci 61.8% 1,010.44
Fibonacci 50% 936.61
Fibonacci 38.2% 862.79
52-Week Low 623.78

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.